Skip to Main Content

Welcome back to part two of STAT’s conversation with Leerink Partners health care analysts Geoff Porges, Seamus Fernandez, and Paul Matteis.

In this edited excerpt, the analysts share their opinions of Trump’s FDA and how new Commissioner Scott Gottlieb could impact drug pricing. They dish on the best management teams in biotech and pharma and point out some under-the-radar industry trends that warrant closer watch.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.